Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q3 2023 Earnings Presentation
16 slides from Hls Therapeutics's earnings presentation, Nov 9, 2023
Slide 1: Q3 2023 Conference Call
Q3 2023 Conference Call November 9, 2023 Craig Millian, CEO Tim Hendrickson, CFO TSX - HLS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Life-changing medicine for Treatment Resistant Schizophrenia
Life-changing medicine for Treatment Resistant Schizophrenia Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 4: Consistent Brand Performance Generates Stable Cash Flow
Consistent Brand Performance Generates Stable Cash Flow US$28.7M US$21.7M 8 Revenue YTD 2023 Direct contribution to consecutive years Adjusted EBITDA YTD 2023 of patient growth in Canada since acquired by HLS (up 1% YTD 2023) Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentatio
Slide 5: CSAN Patient Support Platform is Our Competitive Advantage
CSAN Patient Support Platform is Our Competitive Advantage Patients enrolled in CSAN have a compliance rate 32% higher than those using the leading generic1 Twice as many prescribers were “very satisfied” with CSAN vs. generic platforms2 Key Differentiator for Maintaining the Leading Market Share in
Slide 6: A New Paradigm in the Treatment of Cardiovascular Risk
A New Paradigm in the Treatment of Cardiovascular Risk Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 7: Continued Prescription Momentum
Continued Prescription Momentum Weekly script data since launch 89% increase 2,000 in total prescriptions* 1,500 86% increase in prescribers* 1,000 97% increase 500 in consistent prescribers* 0 (*Q3 2023 compared to Q3 2022) Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation
Slide 8: 2,000 Weekly Rx Milestone Reached in September
2,000 Weekly Rx Milestone Reached in September NRx Momentum in September 13 months to go from 1,000 to 2,000 weekly Rx Number of NRx in September vs July/August Average 2,000 22% increase 1,500 30 months to reach 1,000 weekly Rx 1,000 500 0 July/Aug Average September Toronto Stock Exchange (TSX) - H
Slide 9: Executing on Priorities for Vascepa Growth & Profitability
Executing on Priorities for Vascepa Growth & Profitability Adapt go-to-market Updated promotional services agreement with Pfizer model Working through coverage implementation with BC Pharmacare Improve reimbursement Increase in patient authorization volumes in Ontario & ongoing dynamics Secure impro
Slide 10: Growing Evidence Supporting Vascepa Clinical Benefits
Growing Evidence Supporting Vascepa Clinical Benefits • Eicosapentaenoic Acid (EPA) Modulated Expression Of Proteins Linked To Platelet Activation In Vascular Endothelial Cells During Inflammation Vascular 2023 • Combination Of Eicosapentaenoic Acid (EPA) And A Statin Increased Expression Of Detoxif
Slide 11: Financial Strength: Solid Foundation to support our growth
Financial Strength: Solid Foundation to support our growth Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update
Slide 12: Record Product Sales in Q3 of $13.4M
Record Product Sales in Q3 of $13.4M Annual Vascepa Revenue (CDN$ M) % change TARGET: Q3 % (constant $18-$20M (USD$ millions) 2023 change currency) Total Revenue 16.0 +2% +4% $12.3 $12.7 Total Product Sales 13.4 +2% +4% $7.4 Canadian Product Sales 10.2 +6% +9% $1.9 2020 2021 2022 2023 YTD 2023 Outlo
Slide 13: Vascepa to Become a Positive Contributor to Adjusted EBITDA
Vascepa to Become a Positive Contributor to Adjusted EBITDA Adjusted EBITDA Contribution ACTUAL (YTD 2023) OUTLOOK (H2 2024) Vascepa to generate positive contribution to Adjusted EBITDA in 2H 2024 direct contribution to continued strong Adjusted EBITDA: contribution to Adjusted EBITDA $21.7M direct
Slide 14: Strong Balance Sheet with Capacity for Expansion
Strong Balance Sheet with Capacity for Expansion Summary Balance Sheet & Capitalization Share Buyback (US$ millions) At Dec 31, 2022 At Sept 30, 2023 • Return of capital via NCIB (share buyback) • >3x increase in Q3 compared to Q1 & Q2 Cash and Cash Equivalents 20.7 21.8 1 Senior Secured Term Loan a
Slide 15: Stable Cash Flow and Organic Growth Potential
▪ Stable cash flow & significant organic growth potential ▪ Near-term operational catalysts for Vascepa ▪ Improved promotional effectiveness ▪ Enhanced reimbursement ▪ Target positive Adj. EBITDA in 2H 2024 ▪ >3x increase in share buy-back ▪ Financial capacity for future expansion Toronto Stock Exch
Slide 16: Q3 2023 Conference Call
Q3 2023 Conference Call November 9, 2023 Craig Millian, CEO Tim Hendrickson, CFO TSX - HLS